Our news

Current news

:: 06. May 2024

End of recruitment

INNODIA is happy to announce that the Ver-A-T1D study has successfully randomized 135 participants.

:: 22. April 2024

The end of an era and beginning of a new one: INNODIA HARVEST Final annual meeting

As we started with the first annual meeting of INNODIA in Leuven (Belgium), back in 2016, we are now reaching the end of INNODIA HARVEST at the same location. Approximately 130 participants gathered together in-person and remotely to look back on the project.

News 2023

:: 21. November

MELD-ATG clinical trial - one of the last participants treated in Hannover, Germany

Jette is one of the last participants treated in the INNODIA clinical trial MELD-ATG.

:: 09. October 2023

Study suggests treatment with antiviral drugs could preserve beta cell function in children newly diagnosed with type 1 diabetes

A recent study, led by Dr Ida Maria Mynarek and Professor Knut Dahl-Jørgensen, from the Oslo University Hospital, Oslo, Norway, was presented on October 4, 2023 at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany. The study suggests that antiviral drugs could help protect insulin-producing cells in the pancreas in children newly diagnosed with type 1 diabetes (T1D).

:: 01. March 2023

Imcyse Announces Completion of Enrollment

Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced completion of patient enrollment in its Phase 2 IMPACT (IMCY-0098 Proof of ACtion in Type 1 Diabetes) trial of its lead product candidate IMCY-0098, a proinsulin-derived ImotopeTM engineered to halt the progression and prevent early-onset Type 1 diabetes (T1D).

:: 01. March 2023

2023 George Eisenbarth Memorial Lecture award

INNODIA PI The Prof. Decio Eizirik after receiving the 2023 George Eisenbarth Memorial Award at the annual nPOD conference.

:: 03. February 2023

IMPACT has reached its target; screening closed!

After 27 months of incredible dedication - for a big part during pandemic times - IMPACT has reached its enrolment target and is closing screening of newly diagnosed adult patients.

:: 31. January 2023

Decio L. Eizirik wins the George Eisenbarth Memorial Lecture

Congratulations to Dr. Decio L. Eizirik, the recipient of the 2023 George Eisenbarth Memorial Lecture at the 15th annual Network for Pancreatic Organ Donors with Diabetes (nPOD) meeting.


:: 02. Dezember 2022

The role of the family physician

How can general practitioners support screening, prevention and intervention of type 1 diabetes?

:: 30. November 2022

MELD-ATG is halfway!

MELD-ATG is thrilled to have reached half of the participants we need to include in the study.

:: 18. November 2022

INNODIA project - Progetto INNODIA

For the occasion of World Diabetes Day and Diabetes Awareness Month, Caterina Formichi from the INNODIA team in Siena, was asked to write an article in Cibum, an Italian online platform aimed at sharing scientific information on the correct lifestyles to live healthy.

:: 18. November 2022

BREAKING: TZIELD approved by FDA to delay the onset of T1D

A huge step for mankind: First ever disease-modifying drug for Type 1 Diabetes approved by FDA.
Let us hope this is the first step on the path to eradicate the disease. INNODIA investigators will do all they can to help speed up this process!

:: 15. November 2022

Manuela Battaglia becomes Managing Director of the INNODIA iVZW

We are proud to announce that Manuela Battaglia, Ph.D. has been named Managing Director of the INNODIA iVZW.
Congratulations, Dr. Battaglia!

:: 31. October 2022

The pathogenesis of Type 1 Diabetes

There is great motivation among researchers to act on the pathogenesis of Type 1 Diabetes. What do we know about how T1D develops? And what starting points does this process offer?

Article by Prof. C. Mathieu in Artsenkrant, a magazine for medical doctors and specialists, focusing on a number of disciplines, the latest medical news. [Dutch and French only]

:: 14. October 2022

INNODIA featured at Bright Night

The University of Siena took part in BRIGHT-NIGHT, a European Researchers\' event, showing everyone the importance and variety of the world of science, highlighting what happens for INNODIA in the laboratory.

:: 25. August 2022

INNODIA moves to the next stage:
non-for-profit INNODIA iVZW established!

On July 28th 2022 we established INNODIA iVZW, an international, non-profit organization, with its seat in Leuven, Belgium

:: 21. June 2022

Copenhagen get together

INNODIA nurses and study coordinators gathered in Copenhagen.

:: 20. May 2022

Celebrating international Clinical Trials Day

Tomorrow we are celebrating International Clinical Trials Day.

:: 20. May 2022

Master Protocol published

We're pleased to share the news that the INNODIA Master Protocol has now been published in the journal 'Trials'.

:: 11. May 2022

MELD-ATG now open for 5+

INNODIA is beyond proud to have received positive advise to open the MELD-ATG trial for children age 5-11.

:: 04. May 2022

Image-Ver-A-T1D officially started

The first 2 patients have been included in the image-Ver-A-T1D trial so the trial has officially taken off!

:: 23. March 2022

Annual meeting Pisa: INNODIA keeps making progress!

After 2 years of virtual meetings due to the COVID-19 pandemic, the consortium was delighted to finally meet their partners in person again!

:: 16. March 2022

Kick-off annual meeting 2022

Finally the first F2F annual meeting took place since the COVID pandemic.

:: 11. March 2022

INNODIA is expanding!

INNODIA now also welcomes ALL autoantibody positive people in the general population.

:: 09. February 2022

Milestone for Ver-A-T1D

On Monday February 8th, Medizinische Universität Graz celebrated the final visit of the very first participant in the Ver-A-T1D trial.

:: 17. January 2022

First positive data in the IMPACT trial

An interim analysis of IMPACT, the Imcyse clinical trial in collaboration with INNODIA, resulted in positive data! Also recruitment reached its midpoint and the study will soon be initiated in both the US and Australia.

:: 11. January 2022

Sub-hub founded in UZ/KU Leuven

Another sub-hub in Leuven was founded in January 2022.

:: 10. January 2022

Happy New Year!

Happy New Year from the entire INNODIA/INNODIA HARVEST family!

:: 09. December 2021

Approval to use Iscalimab in a lower age group

Enrollment in the Novartis study is now open to people between 12 and 21 years of age.

:: 09. December 2021

Protocol Paper for MELD-ATG

Antithymocyte globulin (ATG), Thymoglobuline, an immunosuppressive agent used in one of the INNODIA clinical trials, has recently shown promise in the treatment of new-onset T1D subjects aged 12–45 years.

:: 23. November 2021

Powerful Webinar about the need for screening and prevention in type 1 diabetes

Armed with strong evidence, 4 leading experts in the field of type 1 diabetes addressed healthcare providers, payors and policy makers about the need for early detection and prevention of the disease.

:: 09. November 2021

EMJ Diabetes Journal

Today, the EMJ Diabetes Journal came out, publishing a congress interview by Prof. Dr. C. Mathieu, explaining INNODIA’s developments and highlighting the future of the field.

:: 22. October 2021

EMA letter of support for INNODIA

The European Medicins Agency supports the adaptation of the INNODIA Master Protocol in Type 1 Diabetes for studies in prevention.

:: 15. October 2021

Thomas Danne wins ISPAD’s Prize of Achievement

INNODIA’s WP5 lead, Prof. Dr. Thomas Danne, has won the Prize of Achievement at the ISPAD2021 conference.

:: 14. October 2021

INNODIA-INNODIA HARVEST exhibits at Health House

INNODIA is honored to have been invited to Health House by the Province of Flemish Brabant (Belgium).

:: 01. October 2021


On Thursday September 30th, INNODIA had an own session at EASD2021, where Prof. Thomas Danne and Prof. Søren Brunak presented and explained all different ongoing studies in the project, as well as their specific work area.

:: 01. October 2021

Winners INNODIA / INNODIA HARVEST Young Scientists Award

Earlier this year, INNODIA/INNODIA HARVEST decided to launch a Young Scientists Award.

:: 24. September 2021

Successful first Webinar

The very first public INNODIA/INNODIA HARVEST Webinar turned out to be a success!

:: 20. September 2021

Start Ver-A-T1D in France

Today InstitutCochin (INSERM) in Paris started recruitment for the INNODIA Ver-A-T1D intervention study.

:: 17. August 2021

Slovenia joining MELD-ATG

As from today, our Slovenian INNODIA partner can start recruitment for the MELD-ATG study.

:: 02. August 2021

INNODIA welcomes Dr. Mark Evans into the INNODIA coordination team.

Although in such sad circumstances, I\'m honoured to join the INNODIA Coordination team at such a momentous time.

:: 30. July 2021

UK now open for Ver-A-T1D recruitment

Birmingham, UK, consented their first patient in the Ver-A-T1D clinical trial.

:: 22. June 2021


INNODIA reached an important milestone by passing the mark of 5000 recruited participants!

:: 8. June 2021

Insightful ImpactSeriesIMI

Extremely insightful ImpactSeriesIMI event on diabetes.

:: 4. June 2021

WP3 annual meeting

Interesting Day!
Annual Meeting of Work Package 3.

:: 20. May 2021

International Clinical Trials Day

On Clinical Trials Day, INNODIA wants to recognize clinical research professionals for what they do to improve public health.

:: 30. April 2021

Event: IMI impact on diabetes

On June 8th, Innovative Medicines Initiative (IMI) organizes a public event with life sessions about the IMI impact on diabetes.

:: 03. March 2021

Eurofins Genomics provides INNODIA with RNA sequencing

In the course of INNODIA WP3 has published multiple papers that included high quality RNAseq done at Eurofins.

:: 15. February 2021

First patient in Ver-A-T1D successfully randomised

BREAKING: Today the first patient in Ver-A-T1D was successfully randomised in the Medizinische Universität Graz.

:: 11. February 2021

International Women In Science Day

How do women working for INNODIA feel about International Day for Women and Girls in Science?

:: 09. February 2021

CFZ533 starts in UZ Leuven

Yesterday February 8th, the first patient at UZ Leuven was treated with Iscalimab.

:: 03. February 2021

First patient treated in IMPACT study

Imcyse, a biopharmaceutical company pioneering the development of specific immunotherapies for the treatment of severe autoimmune diseases, today announced the first patients’ treatment in the IMPACT study in Type 1 Diabetes (T1D).

:: 08. January 2021

Significant paper by Prof. Dr. D. L. Eizirik

A team of researchers led by the Indiana Biosciences Research Institute Diabetes Center’s Scientific Director and ULB Professor Decio L. Eizirik, MD, PhD, WP3 lead in INNODIA....

:: 17. December 2020

First patient treated in MELD-ATG

INNODIA announces the start of the first of 4 clinical trials, in collaboration with the Innovative Medicines Initiative (IMI).

:: 10. December 2020

Cambridge open for recruitment

Cambridge is now open for recruitment!

:: 26. November 2020

First patient screened for MELD-ATG

The first patient in the MELD-ATG trial has been screened in UZ Leuven.

:: 18. November 2020

World Diabetes Day

Not only on November 14th, but every day of the year diabetes nurses should tap themselves on the shoulder for the huge efforts they deliver to support people living with the disease.

:: 21. October 2020

Annual meeting kicks off

Today the INNODIA annual meeting starts for three days straight!

:: 21. October 2020

Prof P. Gillard wins award

INNODIA’s PI Prof Pieter Gillard wins the prestigious Belgian Endocrine Society award.

:: 15. October 2020

Prof T. Battelino wins ISPAD Prize

Congratulations to INNODIA PI Dr T. Battelino who wins the 2020 ISPAD prize for Achievement.

:: 15. October 2020

Press conference in Poland

Last week, INNODIA was brilliantly highlighted in the Polish press.

:: 14. October 2020

Sweden joining INNODIA

We have just started recruiting newly diagnosed type one diabetes patients and their relatives. On October 9, we collected our first screening samples and many relatives are in line for screening, as we have not been able to screen properly since the beginning of summer.

:: 12. October 2020

Artsenkrant features INNODIA

Where are we? What have we achieved? And what are the next steps in INNODIA?

:: 01. October 2020


With a total of 20.106 participants and half a million content views, the EASD2020 virtual annual meeting was a massive success and an interesting journey.

:: 01. October 2020

Spot it, slow it and stop it

To view this article, please click the button below which will redirect you to the IMI-Website.

:: 16. September 2020

Approval to start IMPACT

IMPACT, a study in collaboration with Imcyse SA, is now approved in both Belgium and the UK.

:: 11. September 2020

INNODIA receives regulatory approval to start MELD-ATG

INNODIA received approval from the regulatory authorities to start MELD-ATG, a study for newly diagnosed type one diabetes patients between 5 and 25.

:: 25. August 2020

4 INNODIA trials submitted

4 clinical studies have now been submitted with different authorities for approval, aiming to start soon under the INNODIA framework.

:: 16. July 2020

Dr. Anke M. Schulte about INNODIA in Pharmafakten.

Eine öffentlich-private Forschungspartnerschaft im Rahmen der europäischen Innovative Medicines Initiative – Joint Undertaking (IMI-JU) gibt Typ-1-Diabetikern und ihren Familien neue Hoffnung.

:: 05. June 2020


June 2nd 2020 will always be a day to remember.
INNODIA HARVEST had it’s (virtual) kick off meeting!

:: 28. May 2020

Support ‘Hippo & Friends’ and get yourself the cutest face masks ever!

Hippo & Friends type 1 diabetes foundation supports fundamental scientific research on the cause of type 1 diabetes, but also on new medicines or treatments to prevent and cure the disease.

:: 04. May 2020

INNODIA receives €12m grant to start HARVESTing

INNODIA, a public/private partnership for research aiming at biomarker discovery and prevention of type 1 diabetes in Europe, won a €12m grant from the European Commission’s Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU).

:: 29. April 2020

Europe Supports Autoantibodies as Biomarkers for T1D

An important letter of support is out!

:: 20. April 2020

INNODIA WP 3 leader investigator Prof. Decio Eizirik named Scientific Director of IBRI Diabetes Center.

IBRI Names Decio Eizirik Scientific Director of its IBRI Diabetes Center

:: 16. April 2020

More time to reflect will lead to better insights

As a PhD student, I mainly work from home nowadays due to the measurements taken by the government because of the coronavirus crisis.

:: 14. April

How does someone with three hats experience COVID-19?

Markku Saraheimo is a healthcare professional, a patient and the father of a patient.

:: 08. April 2020

IMI about INNODIA Master Protocol

The INNODIA Master Protocol exmplained

:: 06. April

Message from the PAC chair - Dr. Olivier Arnaud

Quite a strange period in our lives, not only from a personal point of view, but also worldwide, which leads us all to think about what is important.

:: 03. April 2020

PAC member turns to her sewing machine

COVID-19 … What was considered at the beginning as "flu", quickly turned into an extremely contagious virus.

:: 01. April 2020

No greater risk, if well managed!

In these days where COVID-19 fills the headlines, people with chronic diseases, such as T1D, have to be particularly careful to follow the guidance from the health authorities.

:: 27. March 2020

Worth fighting for!

Talking about the Corona virus makes me a bit restless.

:: 26. March 2020

Find your local sources about COVID-19

Some useful links regarding COVID-19

:: 25. March 2020

Corona virus from a scientist perspective

I work on basic research of type 1 diabetes in Dresden, Germany. Our university decided to close down all research labs to prevent employees from getting sick.

:: 23. March 2020

Message from Dr. C. Mathieu about COVID-19

A Message to the current situation

:: 23. March 2020

COVID-19! Say what?

We [Type one diabetes patients] hear it all the time. “Your immune system is not as strong as in a healthy person”, ”You are more vulnerable to pick up infections”, “you’re more likely to catch this”, “you have an increased risk to get that” …

:: 18. March 2020

INNODIA in times of COVID-19

As of today INNODIA decided to pause the clinical study until May 1st.

:: 12. March 2020

We welcome a new INNODIA Satellite in Geel, Belgium

As Type 1 diabetes consultants in UZ Leuven, Dr. Bernard Peene and myself receive first-hand information about the latest and most innovative therapies and Type one diabetes devises (different types of pumps & CGM monitoring systems).

:: 10. February 2020

Three JDRF awards for INNODIA partners

Three INNODIA partners receive an award at the JDRFMissionSummit20.

:: 22. January 2020

Lecture by Prof. Dr. T. Danne

INNODIA PI Prof. Dr. T. Danne lectured in Leuven about ‘Time in range - New paradigms in the treatment of children with Type 1 Diabetes’.

:: 10. January 2020

Another final visit

Svenja, the first INNODIA participant in HKA, had her final visit.

:: 06. January 2020

Prof. C. Mathieu featured in touchENDOCRINOLOGY

Prof. C. Mathieu featured in touchENDOCRINOLOGY

:: 13. December 2019

Visits in Austria

This week WP1 and PAC visited AKH in Vienna and MUG in Graz for an initiation visit.

:: 06. December 2019

Guest lecture by Professor Mark Atkinson

It was a pleasure and an honor to welcome Strategic Advisory Board member Prof. Dr. M. Atkinson in Leuven yesterday!

:: 29. November 2019

Prof. D. Dunger wins new BSPED James M Tanner Award

Congratulations to our INNODIA chief investigator Professor David Dunger.

:: 22. November 2019

Fruitful Annual Meeting Sicily

This year’s annual INNODIA meeting took place in the Ettore Majorana Foundation and International Centre for Scientific Culture in beautiful Erice, an old pre-mediaeval city where three restored monasteries provide an appropriate setting for high intellectual endeavour.

:: 18.11.2019

3000 and counting

Norwich, UK, was the fortunate INNODIA satellite to add another participant to the study, bringing us at a total of 3000! The only way is up!

:: 15.11.2019

Successful World Diabetes Day 2019

Every year, many activities take place around the world to help making World Diabetes Day a global success.

:: 08. November 2019

Significant INNODIA publication in Nature Genetics

The impact of proinflammatory cytokines on the β-cell regulatory landscape provides insights into the genetics of type 1 diabetes.

:: 08. November 2019

World Diabetes Day coming up WDD

WDD is the world’s largest diabetes awareness campaign reaching a global audience of over 1 billion people in more than 160 countries.

:: 20. September 2019

An award for Prof. Otonkoski

INNODIA PI Prof. Dr. Timo Otonkoski receives the prestigious Albert Renold lectorship from EASD2019.

:: 17. September 2019

Innodia opened two more clinical centers in Italy

The staff was very committed and eager to learn and start up recruitment.

:: 09. August 2019

INNODIA is getting ready for the next chapter

Part of INNODIA’s goals is to build a clinical network of high quality...

:: 05. July 2019

Innodia wins the IMI project video contest!

Learn more about type 1 diabetes in our video.

:: 18. June 2019

Final visit of first participant recruited in the Study

Cambridge - April 1st was a very special day for INNODIA. Not because of April Fools’ Day, but because it was the last visit of Annabelle, a very courageous young woman, the first participant with Type 1 Diabetes recruited in the INNODIA study.

:: 03. June 2019

Special guests at our WP1 F2F meeting

Not only did we receive valuable feedback from all sites recruiting participants for INNODIA, but we also had the great pleasure to meet with Lorraine and her daughter Bérénice.

:: 21. May 2019

Shared islet networks in type 1 and 2 diabetes

Joachim Størling, Phd, Senior Researcher, Steno Diabetes Center Copenhagen
INNODIA´s WP3 F2F meeting UZ Leuven

:: 16. May 2019

Viral protein detection and antigen presentation in Enterovirus infected beta cells

Zuzana Marinicova, PhD student at TU Dresden, was one of the speakers at INNODIA’s WP3 F2F meeting in Leuven last week. A lay summary of her presentation.

:: 03. April 2019

Engagement of people living with T1D and their families

Partners of INNODIA are accountable for a growing number of high level, collaborative papers, in our strive to discover novel biomarkers for T1D and achieving a better understanding of the pathogenesis of the disease, thus leading to a path for prevention and cure.

:: 28. March 2019

Recruitment network of samples for biomarker discovery in T1D

The INNODIA consortium is growing each year, with 15 clinical partner institutions who are responsible for recruitment of people with newly diagnosed T1D and first degree family members of people with T1D.

:: 14. February 2019

Milestone of 2000 recruitments in the INNODIA project has been achieved

We´re happy to announce that we are on track to achieving this goal !

:: 07. January 2019

INNODIA was present at the IMI networking event!

On the 14th of December, INNODIA attended the IMI networking event in Dudelange, Luxembourg. This international conference was organized by Luxinnovation and its partners, the Integrated Biobank of Luxembourg, the Laboratoire national de santé, and the Luxembourg Institute of Health in order to celebrate the 10th anniversary of the Innovative Medicines Initiative Joint Undertaking (IMI-JU). IMI-JU is responsible for the funding of medical research projects such as INNODIA.

:: 20. November 2018

INNODIA continues to grow!

3 years after the official start of this 7-year project, INNODIA participants came together for their 3rd annual meeting in Copenhagen, Denmark.

:: 20. November 2018

INNODIA goes all in on communication!

With recruitment going at full speed and all of the centres active, this year’s meeting wanted to focus on the topic of retainment.

:: 13. November 2018

A novel autoantigen in type 1 diabetes has been found!

A team of INNODIA investigators of KULeuven has identified a modified form of the protein GRP78 as a novel autoantigen in human type 1 diabetes.

:: 30. October 2018

10 Years of Lighting the way

INNODIA and members of the Patient advisory committee attended a symposium to celebrate the 10 year anniversary of the Innovative Medicine Initiative

:: 23. October 2018

The Helsinki Biomedical Center was visited by the Patient Advisory Committee of INNODIA!

On Wednesday, members of the Patient Advisory Committee (PAC) visited the Helsinki Biomedical Center.

:: 17. October 2018

IMI celebrates 10th anniversary!

The Innovative Medicines Initiative, the framework under which INNODIA runs, exists a decade!

:: 16. October 2018

A new milestone has been reached!

We are proud to have reached a new milestone! 500 new consented participants have been recruited to the INNODIA study since our last milestone in May.

:: 13. August 2018

Do pancreatic beta cells facilitate their own destruction?

study led by R. Mallone has identified the molecules presented by pancreatic beta cells that mediate their abnormal recognition by the immune system and lead to their destruction in type 1 diabetes (T1D). These discoveries change...

:: 16. July 2018

We were on ADA TV!!

:: 02. July 2018

Job Opening: PhD position in type 1 diabetes research

Prof Chantal Mathieu s research team focuses on the pathogenesis of type 1 diabetes (T1D). Research areas of interest are in particular focusing on...

:: 02. July 2018

Frequent monitoring of c-peptide levels

INNODIA researchers from Cambridge have developed a method to monitor what happens to the ability of type 1 diabetes patients to produce their own insulin over time, at home. They asked 32 children and adolescents with type 1 diabetes to collect a drop of blood at home on a filter paper card, also called ‘dried blood spot’, every week, in the first year from diagnosis.

:: 02. July 2018

Full day meeting at King’s College in London

Last Tuesday, around 60 nurses, clinicians and researchers from 12 different European countries gathered for a full day meeting at King’s College, London, to discuss the progress on the INNODIA clinical study. Members of the communication team, representatives of JDRF and the Patient Advisory Committee also attended the meeting.

:: 13. June 2018

New biomarker for T1D?

T1D scientists have been trying for a long time to find ways to measure changes to the immune system in the blood that could tell us what is happening to the islets and beta cells in the pancreas...

:: 28. May 2018

We have reached a milestone!

We have reached a milestone! We have recruited 1000 patients with type 1 diabetes and family members to the INNODIA study!

:: 05. February 2018

We are not all type 1 diabetic, but we are all ‘auto-immune’!

In an article published on Feb, 2nd 2018 in Science Immunology, INNODIA Investigators report that the self-directed autoimmune T lymphocytes that engender the islet destruction of T1D circulate in all individuals, whether diabetic or not, but reach the pancreas only in T1D patients.

:: 09. November 2017

New INNODIA publication

Discovery of a new tracer targeting pancreatic beta cells for non-invasive imaging of
human pancreatic endocrine cells

:: 17. October 2017


The members of the PAC have attended the INNODIA Year 2 meeting in Cambridge in September 2017...

:: 17. October 2017

Annual Meeting Cambridge

Almost 2 years after the official start of its 7-year project, INNODIA participants came together for their second annual meeting in Cambridge...

:: 21. September 2017

Substantial progress made

INNODIA publishes year 1 report

:: 14. February 2017

New video testimony for Innodia

New video testimony for Innodia initiative published by a 38 years T1D experienced person...

"Ariyana Salek is a 10 year old – she developed Type 1 Diabetes (T1D) at the age of 6 years old. Her brother Arman (7 years old) and mother Tracey have volunteered to join INNODIA. The volunteers give a small amount of blood to see if they have the characteristic antibodies suggesting future risk for developing T1D".

:: 11. November 2016

IMI-supported INNODIA reaches crucial milestone

First patient enrolled in the INNODIA European sample collection effort

:: 11. November 2016

INNODIA videos published

Find out who drives INNODIA

:: 01. November 2016

INNODIA First Annual meeting Oct 10-12, 2016

Nine months after the INNODIA kick-off meeting participants gathered for the first Annual Meeting from Oct. 10.-12., 2016 in Leuven, Belgium...

:: 01. November 2016

INNODIA First Annual meeting Oct 10-12, 2016

Nine months after the INNODIA kick-off meeting participants gathered for the first Annual Meeting from Oct. 10.-12., 2016 in Leuven, Belgium...

Prof. Chantal Mathieu, KU Leuven

:: 10. March 2016

INNODIA Kick-off meeting held in Frankfurt Jan 17th - 19th

More than 70 scientists have attended the INNODIA Kick-off meeting in Frankfurt/Main on Jan 17th – 19th representing the 33 INNODIA participants from academia, EFPIA and patient organizations...

:: 10. March 2016

INNODIA consortium launched on Nov. 1st 2015

INNODIA was launched on Nov 1st 2015 in response to the first call of the Innovative Medicines Initiative (IMI) under IMI2 by an international consortium including...

:: 10. March 2016

INNODIA consortium launched on Nov. 1st 2015

INNODIA was launched on Nov 1st 2015 in response to the first call of the Innovative Medicines Initiative (IMI) under IMI2 by an international consortium including...